Publications by authors named "John Brognard"

Claim this Profile
C
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.
Andrii Gorelik, Joao A Paulo, Christina B Schroeter, Melanie Lad, Abigail Shurr, John Brognard

Proc Natl Acad Sci U S A· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer.
Meghri Katerji, Knickole L Bergman, Eric Lindberg, Maxine R Rubin, Marwa Afifi, John F Brognard

J Biol Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example.
Pedro Torres-Ayuso, John Brognard

Expert Opin Ther Targets· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.
Amy L Funk, Meghri Katerji, Marwa Afifi, Katherine Nyswaner, Carolyn C Woodroofe, John Brognard

Sci Signal· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth.
Amy L Funk, Meghri Katerji, Marwa Afifi, Katherine Nyswaner, Carolyn C Woodroofe, John Brognard

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas.
Sweta Dash, Sabrina Hanson, Ben King, Katherine Nyswaner, Kelcie Foss, John Brognard

J Biol Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC.
Kamila Karpińska, Dawid Mehlich, Venkata R Sabbasani, Michał Łomiak, Pedro Torres-Ayuso, John Brognard

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of EGFR and PI3K with a single drug.
Meghri Katerji, Maxine R Rubin, John Brognard

Nat Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.
Triet Nguyen, Francesca A Carrieri, Nick Connis, Audrey Lafargue, Jinhee Chang, John Brognard

Mol Cancer Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.
Triet Nguyen, Francesca Anna Carrieri, Nick Connis, Audrey Lafargue, Jinhee Chang, John Brognard

Mol Cancer Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Pedro Torres-Ayuso, Meghri Katerji, Dawid Mehlich, Sophia A Lookingbill, Venkata R Sabbasani, John Brognard

Cell Chem Biol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer.
Pedro Torres-Ayuso, John Brognard

Mol Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Evgeniia Prokhorova, Florian Zobel, Rebecca Smith, Siham Zentout, Ian Gibbs-Seymour, John Brognard

Nat Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
Pedro Torres-Ayuso, Elvira An, Katherine M Nyswaner, Ryan C Bensen, Daniel A Ritt, John Brognard

Cancer Discov· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Ryan Bensen, John Brognard

Int J Mol Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Van T Hoang, Katherine Nyswaner, Pedro Torres-Ayuso, John Brognard

J Biol Chem· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets.
Pedro Torres-Ayuso, John Brognard

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orange is the new black: Kinases are the new master regulators of tumor suppression.
Elvira An, John Brognard

IUBMB Life· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.
Anna A Marusiak, Monika K Prelowska, Dawid Mehlich, Michal Lazniewski, Klaudia Kaminska, John Brognard

Oncogene· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors.
Pedro Torres-Ayuso, John Brognard

Cancer Discov· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase Cα gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
Julia A Callender, Yimin Yang, Gema Lordén, Natalie L Stephenson, Alexander C Jones, John Brognard

Proc Natl Acad Sci U S A· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.
Pedro Torres-Ayuso, Sudhakar Sahoo, Garry Ashton, Elvira An, Nicole Simms, John Brognard

NPJ Genom Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.
Andrew M Hudson, Natalie L Stephenson, Cynthia Li, Eleanor Trotter, Adam J Fletcher, John Brognard

Sci Signal· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.
Zoe C Edwards, Eleanor W Trotter, Pedro Torres-Ayuso, Phil Chapman, Henry M Wood, John Brognard

Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.
Maria Romina Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, John Brognard

Cancer Cell· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis